Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

AXITINIB IN ADVANCED / METASTATIC RENAL CELL CARCINOMA - A NON-INTERVENTIONAL STUDY OF REAL WORLD TREATMENT OUTCOMES IN PATIENTS RECEIVING 2ND LINE AXITINIB AFTER 1ST LINE SUNITINIB (ADONIS)

NCT02184416 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT02184416
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02184416 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
AXITINIB IN ADVANCED / METASTATIC RENAL CELL CARCINOMA - A NON-INTERVENTIONAL STUDY OF REAL WORLD TREATMENT OUTCOMES IN PATIENTS RECEIVING 2ND LINE AXITINIB AFTER 1ST LINE SUNITINIB (ADONIS)
Lead sponsor
Pfizer
Phase
Observational
Overall status
Completed
Start date
October 31, 2014
Completion date
September 30, 2022
Enrollment
554 (actual)
Sites
110

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic renal cell carcinoma (mrcc)